✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Alkem Laboratories Ltd.

ALKEM

Market Cap
₹60,210 Cr.
P/E
27.96

Alkem Laboratories Ltd.

  • Alkem Laboratories
  • Abbott India
  • Aurobindo Pharma
  • TJI Pharma
FAQs on Alkem Laboratories Ltd. Shareprice

Alkem Laboratories has given better returns compared to its competitors.
Alkem Laboratories has grown at ~17.15% over the last 9yrs while peers have grown at a median rate of 11.29%

Alkem Laboratories is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Alkem Laboratories is 27.96, while 3 year average PE is 30.83.
Also latest EV/EBITDA of Alkem Laboratories is 23.58 while 3yr average is 23.18.

View FAQ's On Business
Growth Table
  • Alkem Laboratories Ltd.
  • Abbott India
  • Aurobindo Pharma
Balance Sheet
  • Alkem Laboratories Ltd.
  • Abbott India
  • Aurobindo Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Alkem Laboratories Ltd.
  • Abbott India
  • Aurobindo Pharma
Cash Flow
  • Alkem Laboratories Ltd.
  • Abbott India
  • Aurobindo Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Alkem Laboratories Ltd.
  • Abbott India
  • Aurobindo Pharma
Quarterly Results
  • Alkem Laboratories Ltd.
  • Abbott India
  • Aurobindo Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Alkem Laboratories Ltd. Financials

Balance sheet of Alkem Laboratories is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Alkem Laboratories is increasing.
Latest debt of Alkem Laboratories is -₹715.98 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹1,933.99 Crs.

Yes, profit is increasing.
The profit of Alkem Laboratories is ₹2,197 Crs for TTM, ₹1,796 Crs for Mar 2024 and ₹984 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Alkem Laboratories latest dividend payout ratio is 26.63% and 3yr average dividend payout ratio is 37.36%

Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech